Although this finding emerges from the study of a single toxic molecule and the protein that it transports, Whitehead Member David Sabatini says this phenomenon could be leveraged more broadly.
"Our work suggests a different strategy for cancer therapy that takes advantage of the capacity of a cancer cell to take up something toxic that a normal cell does not," says Sabatini, who is also a professor of biology at MIT and a Howard Hughes Medical Institute (HHMI) investigator. "As a result, that toxic molecule would kill the cancer cell. By identifying transporters on the surface of cancer cells, you might be able to find a molecule that a specific transporter would carry into the cell, and that molecule would be toxic to that cell. You really could have something that's much more selective to cancer cells."
The Sabatini lab's research is published online today in the journal Nature Genetics.
Kivanc Birsoy, a postdoctoral researcher in Sabatini's lab and first author of the Nature Genetics paper, used a special line of haploid cells developed by former Whitehead Fellow Thijn Brummelkamp to screen for genes that assist cellular entry of 3-bromopyruvate's (3-BrPA), a potential cancer drug in clinical development. 3-BrPA is thought to work by inhibiting glycolysis, a cellular process that releases energy by splitting glucose molecules. Because many cancer cells are heavily dependent on the upregulation of glycolysis, drugs that interrupt this pathway may be effective in targeting these glycolytic cancer cells.
From the screen and massively parallel sequencing, Birsoy identified the gene that codes for the protein monocarboxylate transporter 1 (MCT1), which is necessary and sufficient for 3-BrPA's transport into cells, where the toxic molecule ultimately kills them. In fact, the level of MCT1 on the surface of glycolytic tumor cells is a predictor of those cells' sensitivity to 3-BrPA—the higher the cells' expression of MCT1, the more sensitive they are to 3-BrPA. This holds true in in vitro and in vivo models across multiple lines of human cancer cells.
The correlation between MCT1 concentration and 3-BrPA sensitivity could be used to help determine how certain malignant tumors are treated.
"This study makes MCT1 a biomarker for 3-BrPA," says Birsoy. "So in the future, if 3-BrPA is approved as a drug, presumably you could predict if a patient's cancer tumor is going to be sensitive by looking at the levels of this molecule. No tumor without MCT1 would respond to treatment with 3-BrPA."
This work was supported by the National Institutes of Health (CA103866), the David H. Koch Institute for Integrative Cancer Research, the Jane Coffin Childs Memorial Fund, and the National Science Foundation (NSF).
Written by Nicole Giese Rura
David Sabatini's primary affiliation is with Whitehead Institute for Biomedical Research, where his laboratory is located and all his research is conducted. He is also a Howard Hughes Medical Institute investigator and a professor of biology at Massachusetts Institute of Technology.
"MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors"
Nature Genetics, December 2, 2012, online.
Kivanc Birsoy (1,2), Tim Wang (1), Richard Possemato (1,2), Omer H Yilmaz (1,2), Catherine E Koch (1,2), Walter W Chen (1,2), Amanda W Hutchins (1,2), Yetis Gultekin (1,2), Tim R Peterson (1,2), Jan E Carette (1,6), Thijn R Brummelkamp (1,6), Clary B Clish (3) and David M Sabatini (1).
1. Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, USA.
2. Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, USA.
3. Broad Institute, Cambridge, Massachusetts, USA.
4. David H Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts, USA.
5. Howard Hughes Medical Institute, MIT, Cambridge, Massachusetts, USA.
6. Present addresses: Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA (J.E.C.) and Department of Biochemistry, Netherlands Cancer Institute, Amsterdam, The Netherlands (T.R.B.)
Nicole Rura | Source: EurekAlert!
Further information: www.wi.mit.edu
Further Reports about: 3-BrPA > Biomedical > Broad Institute > Cancer > cancer cells > cell death > Genetics > information technology > Integrative Medizin > MCT1 > Medical Wellness > Nature Genetics > Nature Immunology > Sabatini > toxic molecule
More articles from Life Sciences:
New way to improve antibiotic production
18.06.2013 | Norwich BioScience Institutes
Missing enzyme linked to drug addiction
18.06.2013 | The Endocrine Society
... two engines aircraft project “Elektro E6”.
The countdown has been started for opening the gates again for the worldwide leading aviation and space event in Le Bourget, Paris from June 17th - 23rd, 2013.
EADCO & PC-Aero will present at the Paris Air Show in Hall H4 booth F-7 their new future aircraft and innovative project: ...
Siemens scientists have developed new kinds of ceramics in which they can embed transformers.
The new development allows power supply transformers to be reduced to one fifth of their current size so that the normally separate switched-mode power supply units of light-emitting diodes can be integrated into the module's heat sink.
The new technology was developed in cooperation with industrial and research partners who ...
Cheaper clean-energy technologies could be made possible thanks to a new discovery.
Led by Raymond Schaak, a professor of chemistry at Penn State University, research team members have found that an important chemical reaction that generates hydrogen from water is effectively triggered -- or catalyzed -- by a nanoparticle composed of nickel and phosphorus, two inexpensive elements that are abundant on Earth. ...
The Fraunhofer Institute for Laser Technology ILT generated a lot of interest at the LASER World of Photonics 2013 trade fair with its numerous industrial laser technology innovations.
Its highlights included beam sources and manufacturing processes for ultrashort laser pulses as well as ways to systematically optimize machining processes using computer simulations. There was even a specialist booth at the fair dedicated to the revolutionary technological potential of digital photonic production.
Now in its fortieth year, LASER World ...
It's not reruns of "The Jetsons", but researchers working at the National Institute of Standards and Technology (NIST) have developed a new microscopy technique that uses a process similar to how an old tube television produces a picture—cathodoluminescence—to image nanoscale features.
Combining the best features of optical and scanning electron microscopy, the fast, versatile, and high-resolution technique allows scientists to view surface and subsurface features potentially as small as 10 nanometers in size.
The new microscopy technique, described in the journal AIP Advances,* uses a beam of electrons to excite a specially ...
18.06.2013 | Materials Sciences
18.06.2013 | Health and Medicine
18.06.2013 | Life Sciences
14.06.2013 | Event News
13.06.2013 | Event News
10.06.2013 | Event News